vs
Side-by-side financial comparison of Maase Inc. (MAAS) and Neuphoria Therapeutics Inc. (NEUP). Click either name above to swap in a different company.
Neuphoria Therapeutics Inc. is the larger business by last-quarter revenue ($15.0M vs $9.9M, roughly 1.5× Maase Inc.).
Neuphoria Therapeutics Inc is a clinical-stage biopharmaceutical company focused on researching and developing innovative targeted therapies for unmet medical needs in neurological and psychiatric conditions, including anxiety, treatment-resistant depression, and other central nervous system disorders. Its core R&D efforts prioritize delivering safer, more effective treatment options for patient groups with limited existing care alternatives.
MAAS vs NEUP — Head-to-Head
Income Statement — Q2 FY2023 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $9.9M | $15.0M |
| Net Profit | — | $11.3M |
| Gross Margin | 78.7% | — |
| Operating Margin | -55.9% | 79.8% |
| Net Margin | — | 75.1% |
| Revenue YoY | — | — |
| Net Profit YoY | — | — |
| EPS (diluted) | — | $6.55 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $10.9M | $17.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $31.6M | $26.0M |
| Total Assets | $47.0M | $30.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 25 | — | $17.0M | ||
| Q4 22 | $10.9M | — |
| Q1 25 | — | $26.0M | ||
| Q4 22 | $31.6M | — |
| Q1 25 | — | $30.7M | ||
| Q4 22 | $47.0M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-18.2M | $11.5M |
| Free Cash FlowOCF − Capex | $-18.3M | — |
| FCF MarginFCF / Revenue | -184.4% | — |
| Capex IntensityCapex / Revenue | 1.0% | — |
| Cash ConversionOCF / Net Profit | — | 1.02× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 25 | — | $11.5M | ||
| Q4 22 | $-18.2M | — |
| Q1 25 | — | — | ||
| Q4 22 | $-18.3M | — |
| Q1 25 | — | — | ||
| Q4 22 | -184.4% | — |
| Q1 25 | — | — | ||
| Q4 22 | 1.0% | — |
| Q1 25 | — | 1.02× | ||
| Q4 22 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MAAS
| Wealth management | $7.8M | 78% |
| Insurance consulting | $1.0M | 10% |
| Other | $975.0K | 10% |
| Asset management | $168.0K | 2% |
NEUP
Segment breakdown not available.
